Publicaciones en las que colabora con Juan Carlos Montero González (9)

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2014

  1. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2009

  1. DNA DSBs Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

    CLINICAL LYMPHOMA & MYELOMA

  2. Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

    Blood, Vol. 113, Núm. 16, pp. 3781-3791

2008

  1. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

    Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225

  2. Expression of c-Kit isoforms in multiple myeloma: Differences in signaling and drug sensitivity

    Haematologica, Vol. 93, Núm. 6, pp. 851-859

  3. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

    Haematologica, Vol. 93, Núm. 1, pp. 57-66

  4. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells

    British Journal of Haematology, Vol. 141, Núm. 4, pp. 470-482

2005

  1. Multifunctional role of Erk5 in multiple myeloma

    Blood, Vol. 105, Núm. 11, pp. 4492-4499